• 1
    Cooper MJ, Hutchins GM, Cohen PS, Helman LJ, Mennie RJ, Israel MA. Human neuroblastoma tumor cell lines correspond to the arrested differentiation of chromaffin adrenal medullary neuroblasts. Cell Growth Diff 1990; 1: 14959.
  • 2
    Cushing P, Wolbach P. The transformation of a malignant paravertebral sympathicoblastoma into a benign ganglioneuroma. Am J Pathol 1927; 3: 20315.
  • 3
    Evans AE, Gerson J, Schnaufer L. Spontaneous regression of neuroblastoma. Natl Cancer Inst Monogr 1976; 44: 4954.
  • 4
    Evans AE, Silber JH, Shpilsky A, D'Angio GJ. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol 1996; 14: 250410.
  • 5
    Pinkerton CR, Blanc Vincent MP, Bergeron C, Fervers B, Philip T. Induction chemotherapy in metastatic neuroblastoma: does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC). Eur J Cancer 2000; 36: 180815.
  • 6
    Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002; 1: 11723.
  • 7
    Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI-571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002; 20: 325334.
  • 8
    Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC. Expression of stem cell factor and c-Kit in human neuroblastoma. Blood 1994; 84: 346572.
  • 9
    Beck D, Gross N, Brognara CB, Perruisseau G. Expression of stem cell factor and its receptor by human neuroblastoma cells and tumors. Blood 1995; 86: 31328.
  • 10
    Dominici C, Negroni A, Romeo A, Castello MA, Clerico A, Scopinaro M, Mauro F, Raschella' G. Association of near-diploid DNA content and N-myc amplification in neuroblastomas. Clin Exp Metastasis 1989; 7: 20111.
  • 11
    Smithey BE, Pappo AS, Hill DA. c-Kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am J Surg Pathol 2002; 26: 48692.
  • 12
    Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999; 86: 34963.
  • 13
    Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans Ae, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, response to treatment. J Clin Oncol 1993; 11: 146677.
  • 14
    Pietsch T, Kyas U, Steffens U, Yakisan E, Hadam MR, Ludwing WD, Zsebo K, Welte K. Effects of human stem cell factor (c-Kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. Blood 1992; 80: 1199206.
  • 15
    Scarpa S, Dominici C, Grammatico P, Del Porto G, Raschella' G, Castello M, Forni G, Modesti A. Establishment and characterization of a human neuroblastoma cell line. Int J Cancer 1989; 43: 64551.
  • 16
    Matsushima H and Bogenmann E. Bi-modal differentiation pattern in a new human neuroblastoma cell line in vitro. Int J Cancer 1992; 51: 2508.
  • 17
    Reynolds CP, Biedler JL, Spengler BA, Reynolds DA, Ross RA, Frenkel EP, Smith RG. Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst 1986; 76: 37587.
  • 18
    Sadee W, YU VC, Richards ML, Preis PN, Schwab MR, Brodsky FM, Biedler JL. Expression of neurotransmitter receptors and myc proto-oncogenes in subclones of a human neuroblastoma cell line. Cancer Res 1987; 47: 520712.
  • 19
    Longo L, Christiansen H, Christiansen NM, Cornaglia-Ferraris P, Lampert F. N-myc amplification at chromosome band 1p32 in neuroblastoma cells as investigated by in situ hybridization. J Cancer Res Clin Oncol 1988; 114: 63640.
  • 20
    Novak-Hofer I, Amstutz HP, Morgenthaler JJ, Schubiger PA. Internalization and degradation of monoclonal antibody chCE7 by human neuroblastoma cells. Int J Cancer 1994; 57: 42732.
  • 21
    Ferrari N, Pfahl M, Levi G. Retinoic acid receptor gamma1 (RARgamma1) levels control RARbeta2 expression in SK-N-BE2(c) neuroblastoma cells and regulate a differentiation-apoptosis switch. Mol Cell Biol 1998; 18: 648292.
  • 22
    Seeger RC, Danon YL, Rayner SA, Hoover F. Definition of a Thy-1 determinant on human neuroblastoma, glioma, sarcoma, teratoma cells with a monoclonal antibody. J Immunol 1982; 128: 9839.
  • 23
    Tanno B, Negroni A, Vitali R, Pirozzoli MC, Cesi V, Mancini C, Calabretta B, Raschella' G. Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms. J Biol Chem 2002; 277: 2317280.
  • 24
    Negroni A, Venturelli D, Tanno B, Amendola R, Ransac S, Cesi V, Calabretta B, Raschella' G. Neuroblastoma specific effects of DR-nm23 and its mutant forms on differentiation and apoptosis. Cell Death Differ 2000; 7: 84350.
  • 25
    Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-Kit receptor tyrosine kinase activity by STI-571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 92532.
  • 26
    Kapur R and Zhang L. A novel mechanism of cooperation between c-Kit and erythropoietin receptor: stem cell factor induces the expression of Stat5 and erythropoietin receptor, resulting in efficient proliferation and survival by erythropoietin. J Biol Chem 2001; 276: 10996.
  • 27
    Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, 13-cis-retinoic acid. N Engl J Med 1999; 341: 116573.
  • 28
    Wainwright LJ, Lasorella A, Iavarone A. Distinct mechanisms of cell cycle arrest control the decision between differentiation and senescence in human neuroblastoma cells. Proc Natl Acad Sci U S A 2001; 98: 9396400.
  • 29
    Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A. Expression of c-Kit receptor in normal and transformed human non-lymphoid tissues. Cancer Res 1992; 52: 613943.
  • 30
    Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692703.
  • 31
    Dominici C, Nicotra Mr, Bosman C, Gallo P, Padula A, Pietsch T, Natali PG. Expression of c-Kit and stem cell factor is associated with N-myc gene amplification in neuroblastoma. Proc Am Assoc Cancer Res 1996; 37: 2201.
  • 32
    Lennartsson J, Blume-Jensen P, Hermanson M, Ponten E, Carlberg M, Ronnstrand L. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 1999; 18: 554653.
  • 33
    Sawyers CL. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer Cell 2002; 1: 135.
  • 34
    Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1: 316.
  • 35
    Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD. STI-571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20: 50548.
  • 36
    Natali PG, Nicotra MR, Winkler AB, Cavaliere R, Bigotti A, Ullrich A. Progression of human cutaneous melanoma is associated with loss of expression of c-Kit proto-oncogene receptor. Int J Cancer 1992; 53: 197201.
  • 37
    Pietsch T, Nicotra MR, Fraioli R, Wolf HK, Mottolese M, Natali PG. Expression of the c-Kit receptor and its ligand SCF in non-small-cell lung carcinomas. Int J Cancer 1998; 75: 1715.